Lucion, a listed venture capital firm, led a $215m funding round in Intarcia Therapeutics, an American biopharmaceutical company. "Intarcia remains focused on building an innovative and important company in the chronic disease space – one dedicated to addressing serious unmet needs by disrupting the shortcomings of the pill and injection model in chronic disease management," Kurt Graves, Intarcia CEO.